DTIL

+ Watchlist + Portfolio

Precision BioSciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.50
52-Week Range: $3.53 – $9.62
Market Cap: $240.69M
P/E (TTM): —
EPS (TTM): -1.32
Dividend Yield: —

Advanced Metrics

Price/Book: 5.09
PEG Ratio: —
Return on Equity: -135.15%
Return on Assets: -19.37%
Gross Margin: 100.00%
Operating Margin: -80.78%
Profit Margin: -117.04%
Current Ratio: 12.82
Debt/Equity: 0.62
Total Debt: $28.10M
Free Cash Flow: $-16.25M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $175.17M

DTIL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$25.10M	$48.73M	$68.70M	$34.26M
Research & Development	$46.12M	$53.38M	$59.56M	$54.17M
Selling, General & Admin	$41.28M	$39.09M	$35.30M	$32.24M
Operating Expenses	$87.41M	$92.46M	$94.86M	$86.41M
Operating Income	-$62.31M	-$43.74M	-$26.16M	-$52.15M
EBITDA	-$62.79M	-$32.04M	$13.53M	-$42.43M
Pretax Income	-$72.91M	-$42.53M	$7.17M	-$46.61M
Net Income	-$111.64M	-$61.32M	$7.17M	-$45.72M
Diluted EPS	-38.10	-15.96	1.04	-3.56
Diluted Shares	2.93M	3.84M	6.88M	12.83M

DTIL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$189.58M	$116.68M	$85.90M	$110.82M
Receivables	$720.00K	$12.80M	$1.70M	$0.00
Current Assets	$199.10M	$136.36M	$94.99M	$118.74M
Total Assets	$238.17M	$159.78M	$136.39M	$154.42M
Current Liabilities	$59.66M	$49.99M	$14.98M	$8.91M
Long-Term Debt	$22.22M	—	$22.32M	$22.40M
Total Debt	$24.96M	$31.27M	$30.05M	$28.81M
Total Liabilities	$177.74M	$140.92M	$80.00M	$62.17M
Retained Earnings	-$428.31M	-$489.63M	-$482.46M	-$528.19M
Shareholders' Equity	$60.43M	$18.86M	$56.39M	$92.25M
Working Capital	$139.44M	$86.37M	$80.01M	$109.83M

DTIL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$45.75M	-$84.11M	-$58.45M	-$65.84M
Capital Expenditure	-$3.32M	-$2.28M	-$275.00K	-$700.00K
Free Cash Flow	-$49.07M	-$86.39M	-$58.72M	-$66.54M
Depreciation & Amortisation	$9.00M	$8.26M	$4.58M	$2.75M
Stock-Based Compensation	$19.20M	$14.04M	$12.60M	$10.19M
Investing Cash Flow	-$3.32M	$5.83M	-$215.00K	-$634.00K
Financing Cash Flow	$94.98M	$5.39M	$50.45M	$95.16M
Net Change in Cash	$45.91M	-$72.90M	-$8.21M	$28.68M

DTIL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$29.00K	$18.00K	$13.00K	$34.20M	$10.84M
Research & Development	$13.59M	$12.77M	$13.35M	$14.46M	$13.11M
Selling, General & Admin	$8.55M	$9.13M	$7.33M	$7.23M	$6.80M
Operating Expenses	$22.14M	$21.89M	$20.68M	$21.70M	$19.91M
Operating Income	-$22.11M	-$21.88M	-$20.67M	$12.51M	-$9.07M
EBITDA	-$19.51M	-$22.47M	-$20.74M	$20.27M	-$17.49M
Pretax Income	-$20.57M	-$23.52M	-$21.77M	$19.25M	-$18.44M
Net Income	-$20.57M	-$23.52M	-$21.77M	$20.13M	-$18.44M
Diluted EPS	-2.21	-2.13	-1.84	1.05	-0.75
Diluted Shares	9.29M	11.05M	11.82M	19.17M	24.63M

DTIL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$77.22M	$62.24M	$44.87M	$110.82M	$99.37M
Receivables	$4.00K	$0.00	$4.00K	$0.00	—
Current Assets	$82.10M	$70.26M	$51.70M	$118.74M	$108.69M
Total Assets	$124.41M	$108.93M	$93.51M	$154.42M	$143.89M
Current Liabilities	$12.39M	$13.57M	$15.00M	$8.91M	$7.75M
Long-Term Debt	$22.34M	$22.35M	$22.37M	$22.40M	—
Total Debt	$29.75M	$29.45M	$29.13M	$28.81M	$6.05M
Total Liabilities	$75.07M	$74.87M	$76.88M	$62.17M	$67.79M
Retained Earnings	-$503.03M	-$526.55M	-$548.32M	-$528.19M	-$546.63M
Shareholders' Equity	$49.34M	$34.05M	$16.63M	$92.25M	$78.00M
Working Capital	$69.71M	$56.69M	$36.71M	$109.83M	$100.94M

DTIL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$19.05M	-$20.27M	-$15.27M	-$11.25M	-$11.94M
Capital Expenditure	-$314.00K	-$17.00K	—	-$369.00K	-$118.00K
Free Cash Flow	-$19.37M	-$20.29M	-$15.27M	-$11.62M	-$12.05M
Depreciation & Amortisation	$705.00K	$696.00K	$674.00K	$678.00K	$640.00K
Stock-Based Compensation	$2.82M	$2.94M	$2.39M	$2.04M	$1.55M
Investing Cash Flow	-$314.00K	-$12.00K	$17.00K	-$325.00K	-$114.00K
Financing Cash Flow	$10.69M	$5.30M	$1.66M	$77.52M	$745.00K
Net Change in Cash	-$8.68M	-$14.98M	-$13.59M	$65.94M	-$11.31M

Market Snapshot

About

Precision BioSciences, Inc. is a genome editing company developing therapeutic products and technologies based on its proprietary ARCUS platform. The company's ARCUS technology uses engineered nucleases to make precise edits to DNA for treating genetic disorders, cancer, and other diseases. Precision BioSciences has in vivo and ex vivo gene editing programs in development, as well as a food division focused on genome-edited agricultural products. The company is advancing multiple clinical-stage programs and research collaborations in human health applications.